India Business Opportunities Shadowed By Country's Evolving IP Laws
This article was originally published in The Pink Sheet Daily
Implementation of intellectual property protections continues to weigh on India's burgeoning pharmaceutical industry.
You may also be interested in...
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.